Search
ATMPs and CAR-T: the uptake challenge
Advanced therapy medicinal products (ATMPs) are a game changer for improving the life of patients with severe to life-threatening diseases. In hematology, for instance, CAR T cell therapy has shown promising results in tackling different blood cancers.
Read moreWould you sell Peripheral Blood derived Stem Cells?
There are many things that are different in the United States of America (USA) and Europe. Some of these differences are in favour of society in the USA and some in Europe.
Read moreAbstract & travel grant submission
Abstract submission is closed
Abstract procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the time assigned by the…
Abstract & Clinical Case Submission and Travel Grant
Submit your abstract here
Abstract and clinical case procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the time…
EU health policy: limited scope, high ambition
Over the past decades, the European Union (EU) has become more involved in public health policy. A recent study showed that a majority of policymakers even identifies EU health policy as a priority for 2020-20241.
Read moreTackling Sickle Cell Disease: the need for a European approach
Elvie Ingoli, president of the German association of SCD and thalassemia patients, at the 7th EAPM Presidency Conference in Brussels. Sickle Cell Disease (SCD) is relatively new to many parts of Europe.
Read morePress Release: Economic burden of blood disorders in EU is €23 billion
The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.
Read more